Xintela granted 2 million SEK from Vinnova

Lund, Sweden, March 27, 2020 – Xintela has been granted 2 million SEK from Vinnova in the call for “Innovation projects in small and medium-sized companies”. The grant concerns one of the company’s cancer projects and the work to develop targeted therapies for aggressive cancers with integrin 10-binding ADCs. “This is very good news for […]

Xintela publishes positive preclinical results from equine study

Lund, Sweden, 3 February, 2020 – Xintela announces that the results from the company’s stem cell study on horses has now been published in the respected scientific journal The American Journal of Sports Medicine. The publication demonstrates that the stem cell treatment is safe and that it has a significantly positive effect on both cartilage […]

Positive preclinical results in Xintela’s glioblastoma project

Lund, Sweden, December 11, 2019 – Xintela AB (publ) announces positive preclinical results in the glioblastoma project. Xintela has developed function-blocking antibodies that bind to the company’s target integrin a10b1 and identified an antibody that suppresses the growth of glioblastoma tumors in a preclinical model. In order to develop targeted antibody-based therapy for the aggressive […]

Xintela publishes interim report for the third quarter

Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]

Xintela publishes results from glioblastoma study

Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company’s glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela’s marker, integrin a10b1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the […]

Xintela appoints Sven Kili as Chief Operating Officer

Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience […]

Year-end Report 2018

The aim is set for clinical studies The final quarter of the year was very eventful, and successful in terms of both projects and financing. We conducted a directed share issue of MSEK 50 to the German orthopaedic company Bauerfeind AG. In the companies stem-cell project, our aim is to commence clinical trials in Australia. […]

Xintela and Catalent to co-develop brain cancer therapy

Lund, Sverige, 25 oktober 2018 – Xintela tillkännager idag att bolaget har tecknat ett samarbetsavtal med det amerikanska bolaget Redwood BioScience Inc, ett helägt dotterbolag till Catalent, Inc., världsledande inom antibody-drug conjugate (ADC) teknologi för cancerterapi. Parterna avser att gemensamt utveckla en ADC-baserad terapeutisk produkt med första inriktning på hjärntumören glioblastom, den vanligaste och mest […]

SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA

Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]